Найти
Результаты поиска
-
MICROVASCULAR REMODELING AND THE ENDOTHELIAL-APOPTOTIC SWITCH IN LICHEN SCLEROSUS: AN IMMUNOHISTOCHEMICAL STAGE-BASED STUDY
Purpose: To evaluate stage-specific microvascular and apoptotic changes in lichen sclerosus (LS) using CD31, VEGF and CD95 immunohistochemistry. Methods: The article is based on a dissertation cohort of 60 patients with LS. For stage-oriented immunohistochemical analysis, representative dermal samples from progressive-stage lesions (n=15) and chronic-stage lesions (n=15) were examined. Results: In progressive-stage LS, dermal CD31 expression was detected in 33% of samples, VEGF in 80%, and CD95 in 20%, while all three markers were absent in the epidermis. In chronic-stage LS, dermal CD31 expression was present in 53%, VEGF in 20%, and CD95 in 95% of samples, again with no epidermal expression. Morphologically, progressive-stage lesions showed vacuolar interface dermatitis, lymphocytic exocytosis and lichenoid inflammation, whereas chronic-stage lesions were dominated by papillary dermal fibrosis and sclerosis. Malignant progression to squamous cell carcinoma (SCC) was documented in 5 of 60 patients and was associated with ulceration, bleeding, proliferating irregular vessels, epithelial atypia, pathological mitoses and high CD95 expression. Conclusion: LS demonstrates a stage-dependent shift from endothelial activation and neoangiogenesis to endothelial injury, apoptotic remodeling and sclerosis. Combined clinicopathological and immunohistochemical assessment may improve early recognition of unfavorable disease evolution.
-
MICROVASCULAR REMODELING AND THE ENDOTHELIAL-APOPTOTIC SWITCH IN LICHEN SCLEROSUS: AN IMMUNOHISTOCHEMICAL STAGE-BASED STUDY
Purpose: To evaluate stage-specific microvascular and apoptotic changes in lichen sclerosus (LS) using CD31, VEGF and CD95 immunohistochemistry. Methods: The article is based on a dissertation cohort of 60 patients with LS. For stage-oriented immunohistochemical analysis, representative dermal samples from progressive-stage lesions (n=15) and chronic-stage lesions (n=15) were examined. Results: In progressive-stage LS, dermal CD31 expression was detected in 33% of samples, VEGF in 80%, and CD95 in 20%, while all three markers were absent in the epidermis. In chronic-stage LS, dermal CD31 expression was present in 53%, VEGF in 20%, and CD95 in 95% of samples, again with no epidermal expression. Morphologically, progressive-stage lesions showed vacuolar interface dermatitis, lymphocytic exocytosis and lichenoid inflammation, whereas chronic-stage lesions were dominated by papillary dermal fibrosis and sclerosis. Malignant progression to squamous cell carcinoma (SCC) was documented in 5 of 60 patients and was associated with ulceration, bleeding, proliferating irregular vessels, epithelial atypia, pathological mitoses and high CD95 expression. Conclusion: LS demonstrates a stage-dependent shift from endothelial activation and neoangiogenesis to endothelial injury, apoptotic remodeling and sclerosis. Combined clinicopathological and immunohistochemical assessment may improve early recognition of unfavorable disease evolution.